Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.

PloS one - 1 Jan 2013

Jalili Ahmad, Mertz Kirsten D, Romanov Julia, Wagner Christine, Kalthoff Frank, Stuetz Anton, Pathria Gaurav, Gschaider Melanie, Stingl Georg, Wagner Stephan N

Abstract excerpt

Melanoma is one of the most aggressive cancers and its incidence is increasing worldwide. So far there are no curable therapies especially after metastasis. Due to frequent mutations in members of the mitogen-activated protein kinase (MAPK) signaling pathway, this pathway is constitutively active...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biphenyl Compounds
Share to G1 Phase Cell Cycle Checkpoints
Share to Hedgehog Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridines

Share to Smoothened Receptor

Share to Tumor Burden

Share to Vemurafenib

Share to Zinc Finger Protein GLI1

Source

Open in PubMed Open full text

Identifiers

PMID: 23935925
DOI: 10.1371/journal.pone.0069064
PMCID: PMC3728309

Genes

BRAF
SHH
GLI1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23935925-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.PMID 23935925Read ↗

Hedgehog pathway inhibitors: a patent review (2009 – present)Semantic proximity Read ↗

Beyond cyclopamine: Targeting Hedgehog signaling for cancer interventionSemantic proximity Read ↗

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cellsSemantic proximity Read ↗

Targeting the hedgehog pathway to treat basal cell carcinoma.Semantic proximity Read ↗

Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.Semantic proximity Read ↗

Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma TreatmentSemantic proximity Read ↗

Design of Hedgehog pathway inhibitors for cancer treatmentSemantic proximity Read ↗

Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignanciesSemantic proximity Read ↗

Dual Specificity Phosphatase 1 (DUSP1) Provides Mechanistic Link Between Melanoma Cellular Plasticity and Drug ResistanceSemantic proximity Read ↗

Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model.Semantic proximity Read ↗

Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAiSemantic proximity Read ↗

SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.